Gyre Therapeutics Inc. (GYRE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Gyre Therapeutics Inc. (GYRE) has a cash flow conversion efficiency ratio of 0.034x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($4.68 Million) by net assets ($137.41 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Gyre Therapeutics Inc. - Cash Flow Conversion Efficiency Trend (2004–2024)
This chart illustrates how Gyre Therapeutics Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Gyre Therapeutics Inc. balance sheet liabilities for a breakdown of total debt and financial obligations.
Gyre Therapeutics Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Gyre Therapeutics Inc. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shenzhen Shengxunda Technology Co Ltd Class A
SHE:300518
|
0.017x |
|
Turkiye Sinai Kalkinma Bankasi AS
IS:TSKB
|
0.071x |
|
Mobilicom Limited Warrants
NASDAQ:MOBBW
|
-0.330x |
|
Gresgying Digital Energy Technology Co Ltd
SHG:600212
|
0.058x |
|
InnovAge Holding Corp
NASDAQ:INNV
|
0.089x |
|
Chahua Modern Housewares Co Ltd
SHG:603615
|
-0.105x |
|
Northwest Pipe Company
NASDAQ:NWPX
|
0.054x |
|
Beijing Jiaxun Feihong Electrical Co Ltd
SHE:300213
|
0.032x |
Annual Cash Flow Conversion Efficiency for Gyre Therapeutics Inc. (2004–2024)
The table below shows the annual cash flow conversion efficiency of Gyre Therapeutics Inc. from 2004 to 2024. For the full company profile with market capitalisation and key ratios, see GYRE market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $98.40 Million | $-3.64 Million | -0.037x | -101.99% |
| 2023-12-31 | $13.95 Million | $25.89 Million | 1.856x | +1155.49% |
| 2022-12-31 | $72.22 Million | $10.68 Million | 0.148x | +107.25% |
| 2021-12-31 | $41.09 Million | $-83.75 Million | -2.038x | -181.68% |
| 2020-12-31 | $76.07 Million | $-55.05 Million | -0.724x | -13.39% |
| 2019-12-31 | $68.34 Million | $-43.61 Million | -0.638x | -168.10% |
| 2018-12-31 | $119.94 Million | $-28.55 Million | -0.238x | +63.26% |
| 2017-12-31 | $30.77 Million | $-19.94 Million | -0.648x | +43.63% |
| 2016-12-31 | $16.07 Million | $-18.47 Million | -1.149x | -88.93% |
| 2015-12-31 | $31.43 Million | $-19.12 Million | -0.608x | -92.45% |
| 2014-12-31 | $109.08 Million | $-34.48 Million | -0.316x | -4.78% |
| 2013-12-31 | $134.61 Million | $-40.61 Million | -0.302x | +17.38% |
| 2012-12-31 | $175.91 Million | $-64.24 Million | -0.365x | +23.98% |
| 2011-12-31 | $174.29 Million | $-83.72 Million | -0.480x | -131.90% |
| 2010-12-31 | $91.85 Million | $138.30 Million | 1.506x | +528.01% |
| 2009-12-31 | $68.99 Million | $-24.27 Million | -0.352x | +28.58% |
| 2008-12-31 | $57.37 Million | $-28.26 Million | -0.493x | -202.30% |
| 2007-12-31 | $51.58 Million | $24.84 Million | 0.482x | +416.38% |
| 2006-12-31 | $65.00 Million | $-9.89 Million | -0.152x | -194.22% |
| 2005-12-31 | $-162.48 Million | $-26.25 Million | 0.162x | -20.66% |
| 2004-12-31 | $-122.97 Million | $-25.04 Million | 0.204x | -- |
About Gyre Therapeutics Inc.
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis. It is also involved in th… Read more